Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome
We suggest that fondaparinux may be used for TAPS when VKA is not appropriate. Thrombotic recurrence was infrequent, and the number of major bleeding events appeared comparable to conventional therapies.
Authors
- Beverley J. Hunt (ORCID: https://orcid.org/0000-0002-4709-0774)
- Anne Wareing
- V. Collings
- Karen Breen
- Johanna Young (ORCID: https://orcid.org/0000-0002-1788-1903)
- Andrew J. Doyle (ORCID: https://orcid.org/0000-0002-1001-0486)
- J. Bartoli-Abdou (ORCID: https://orcid.org/0000-0002-9294-3174)
- Carl Foskett
- Anthony Hackett
- Fatima Omrani
- Buse Bor
Institutions
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Aarhus University (DK)
Publication Details
- Journal
- Lupus
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1177/09612033241285225
- Citations
- 2
- Primary Topic
- Heparin-Induced Thrombocytopenia and Thrombosis
- Type
- article
- Field-Weighted Citation Impact
- 1.15